Literature DB >> 10193340

In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?

M Turner-Warwick1.   

Abstract

The history of patients with idiopathic pulmonary fibrosis (IPF) shows that the disease may be preceded by a viral-like illness. Although viruses have not been demonstrated, it is possible that viruses were not detected in culture because they do not replicate during latency. We investigated the presence of adenovirus in IPF and interstitial pneumonia associated with collagen vascular disease (CVD-IP), using the nested polymerase chain reaction (PCR) and in situ hybridization (ISH) for the E1A region of the adenovirus genome. Studies were performed on lung tissues obtained by transbronchial lung biopsy from 19 patients with IPF, 10 patients with CVD-IP and, for comparison, 20 patients with sarcoidosis. The E1A DNA was present in 3 out of 19 (16%) cases of IPF, in 5 of 10 (50%) cases of CVD-IP, and in 2 of 20 (10%) cases of sarcoidosis. The incidence of E1A DNA in CVD-IP was significantly higher than that in sarcoidosis (p < 0.05). In patients with IPF and CVD-IP, E1A DNA was more prevalent in patients treated with corticosteroids (6 out of 9 cases; 67%) than in those without it (2 out of 20 cases; 10%) (p < 0.01). ISH studies showed that 1 out of 8 cases of IPF and CVD-IP, in which E1A DNA was detected by PCR, was positive for E1A DNA. We conclude that adenovirus E1A is unlikely to be aetiologically involved in the pathogenesis of idiopathic pulmonary fibrosis or interstitial pneumonia associated with collagen vascular disease. However, a latent adenovirus infection may be reactivated or may newly infect the host following corticosteroid administration.

Entities:  

Mesh:

Year:  1998        PMID: 10193340      PMCID: PMC1765900          DOI: 10.1136/thx.53.2008.s3

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

1.  Identification of inorganic dust particles in bronchoalveolar lavage macrophages by energy dispersive x-ray microanalysis.

Authors:  N F Johnson; P L Haslam; A Dewar; A J Newman-Taylor; M Turner-Warwick
Journal:  Arch Environ Health       Date:  1986 May-Jun

2.  Diffuse interstitial lung disease in tungsten carbide workers.

Authors:  E O Coates; J H Watson
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

3.  Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2.

Authors:  D M Libby; A Gibofsky; M Fotino; S J Waters; J P Smith
Journal:  Am Rev Respir Dis       Date:  1983-05

4.  Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis.

Authors:  J R Chapman; P J Charles; P J Venables; P J Thompson; P L Haslam; R N Maini; M E Turner Warwick
Journal:  Am Rev Respir Dis       Date:  1984-09

5.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

6.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

7.  Graphite pneumoconiosis of electrotypers.

Authors:  E A Gaensler; J B Cadigan; A A Sasahara; E O Fox; H E MacMahon
Journal:  Am J Med       Date:  1966-12       Impact factor: 4.965

8.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.

Authors:  M A Johnson; S Kwan; N J Snell; A J Nunn; J H Darbyshire; M Turner-Warwick
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

9.  Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?

Authors:  J M Vergnon; M Vincent; G de Thé; J F Mornex; P Weynants; J Brune
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

10.  Cryptogenic fibrosing alveolitis and lung cancer.

Authors:  M Turner-Warwick; M Lebowitz; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

View more
  4 in total

1.  Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.

Authors:  C B Keerthisingam; R G Jenkins; N K Harrison; N A Hernandez-Rodriguez; H Booth; G J Laurent; S L Hart; M L Foster; R J McAnulty
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  C Jakubzick; E S Choi; S L Kunkel; H Evanoff; F J Martinez; R K Puri; K R Flaherty; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 3.  The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.

Authors:  Paul D Blanc; Isabella Annesi-Maesano; John R Balmes; Kristin J Cummings; David Fishwick; David Miedinger; Nicola Murgia; Rajen N Naidoo; Carl J Reynolds; Torben Sigsgaard; Kjell Torén; Denis Vinnikov; Carrie A Redlich
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

4.  Viruses as co-factors for the initiation or exacerbation of lung fibrosis.

Authors:  Kevin M Vannella; Bethany B Moore
Journal:  Fibrogenesis Tissue Repair       Date:  2008-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.